
Cingulate Inc.
93
Recent news highlights Cingulate's regulatory interactions with the FDA, including the issuance of a Complete Response Letter for its ADHD drug CTx-1301, as well as continued interest from analysts maintaining buy recommendations.
- In June 2026, the FDA issued a Complete Response Letter to Cingulate requesting additional Chemistry, Manufacturing, and Controls information for its ADHD drug candidate CTx-1301 [N4].
- Cingulate received the FDA Complete Response Letter for CTx-1301 in early June 2026, impacting regulatory progress [N5].
- Despite the FDA CRL, Cingulate's stock showed gains and was noted among top biotech gainers in early June 2026 [N3].
- Analysts including Ascendiant Capital and Roth Capital maintained buy recommendations on Cingulate in late 2025 [N7, N8].
- The company completed Phase 3 safety trials for CTx-1301 and had its NDA accepted by the FDA in October 2025 [N8].
- Cingulate terminated its ATM Agreement in March 2026, removing a prior capital raising mechanism [S2].
Cingulate Inc. is a clinical-stage pharmaceutical company developing treatments for ADHD, with its lead candidate CTx-1301 undergoing regulatory review. The company has not yet generated revenue and has incurred significant net losses since inception. It completed Phase 3 safety trials and submitted an NDA to the FDA, which was accepted in October 2025. However, in June 2026, the FDA issued a Complete Response Letter requesting additional Chemistry, Manufacturing, and Controls information. The company maintains a strong liquidity position with over $23 million in cash and equivalents as of September 30, 2026. Leadership includes experienced executives in pharmaceutical development, finance, legal, and commercial operations. The company operates under a five-year lease for its headquarters in Kansas City, Kansas.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Cingulate Inc. is a clinical-stage pharmaceutical company focused on developing CTx-1301 for ADHD. The company has incurred net losses and has not generated revenue. It completed Phase 3 trials and submitted an NDA accepted by the FDA in October 2025. In June 2026, the FDA issued a Complete Response Letter requesting additional CMC information. As of September 30, 2026, the company had $23.2 million in cash and equivalents and a strong liquidity position with a current ratio of 3.9. The company faces risks typical of preclinical biotech firms, including regulatory, clinical, and financing uncertainties.
Cingulate has advanced its lead ADHD drug candidate through Phase 3 trials and secured FDA acceptance of its NDA, demonstrating progress in clinical development and regulatory engagement. The company maintains a strong liquidity position to support ongoing operations and has an experienced management team with expertise in drug development and commercialization. Positive clinical data and regulatory milestones could enhance the company's prospects in the ADHD treatment market.
The FDA issued a Complete Response Letter requesting additional Chemistry, Manufacturing, and Controls information for CTx-1301, indicating regulatory hurdles remain. The company has not generated revenues and continues to incur net losses, with substantial accumulated deficits. Additional financing will be required to fund operations and development, posing risks related to capital availability. The success of the company is contingent on regulatory approvals and commercial viability of its drug candidates, which remain uncertain.
Cingulate's moat is primarily based on its proprietary ADHD drug candidate CTx-1301, which has undergone extensive clinical development including Phase 3 trials. The company has established manufacturing agreements and regulatory filings that create barriers to entry. However, as a clinical-stage biotech firm without approved products or revenues, its competitive advantage depends heavily on successful regulatory approval and commercialization of its drug candidates.
• Regulatory Risk: The FDA issued a Complete Response Letter for CTx-1301 requesting additional CMC information, indicating regulatory challenges remain before potential approval [N4, N5].
• Financial Risk: The company has incurred net losses since inception and anticipates additional losses until it can generate significant revenue. Additional financing will be needed to fund operations and development [S1].
• Operational Risk: Cingulate depends on successful clinical development, manufacturing agreements, and regulatory approvals. Failure in any of these areas could materially impact the business [S1].
• Liquidity Risk: Although the company had a strong liquidity position as of September 30, 2026, ongoing operations and development require careful cash management and potential future capital raises [S2].
Business trends: Continued clinical development of ADHD drug candidate CTx-1301 with regulatory review and responses to FDA inquiries.
Execution milestones: Completion of Phase 3 trials, NDA submission and acceptance, addressing FDA Complete Response Letter requirements.
Key risks: Regulatory approval uncertainties, need for additional financing, operational dependencies on manufacturing and clinical success.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Cingulate Inc. is a clinical-stage pharmaceutical company focused on developing treatments for ADHD, with its lead product candidate being CTx-1301 [S1].
- The company has not generated revenues and has incurred net losses since inception, with accumulated losses of $132.4 million as of December 31, 2025 [S1].
- Cingulate has entered into agreements with Bend Bioscience for manufacturing process validation batches of CTx-1301, with estimated costs of approximately $7.0 million [S1].
- The company operates its headquarters in Kansas City, Kansas, under a five-year lease commencing June 1, 2025 [S1].
- Cingulate's management team includes experienced executives with backgrounds in pharmaceutical development, finance, legal, and commercial operations [S1].
- The company completed Phase 3 safety trials for CTx-1301 and submitted a New Drug Application (NDA) to the FDA, which was accepted in October 2025 [N8, N7, N6, N3].
- In June 2026, the FDA issued a Complete Response Letter (CRL) requesting additional Chemistry, Manufacturing, and Controls (CMC) information for CTx-1301 [N4, N5].
- Cingulate's stock price was reported at $9.25 as of March 18, 2026 [report_input].
- The company reported a net loss of $7.7 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.53 [S2].
- As of September 30, 2026, Cingulate had cash and cash equivalents of approximately $23.2 million and current assets of about $25.3 million, with current liabilities of $6.5 million, resulting in a current ratio of 3.9 and a cash ratio of 3.58 [S2].
- The company has disclosed risks related to its preclinical stage status, dependence on successful clinical development, regulatory approvals, and the need for additional financing [S1].
- Cingulate terminated its ATM Agreement in March 2026 and has no further obligations under it except customary indemnification [S2].
Generated 2026-11-13
- S1 | 2026-03-18 | 10-K
- S2 | 2026-11-13 | 10-Q
- N1 | 2026-06-05 | www.nasdaq.com | Weekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN | https://www.nasdaq.com/articles/weekly-buzz-phg-kmda-win-fda-nod-fulc-halts-pociredir-rmd-closes-noctrix-deal-nvs-paces
- N2 | 2026-06-04 | www.nasdaq.com | Top Biotech Gainers: ABVX, CING, DRTS, MMED... | https://www.nasdaq.com/articles/top-biotech-gainers-abvx-cing-drts-mmed
- N3 | 2026-06-03 | www.nasdaq.com | Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL | https://www.nasdaq.com/articles/top-biotech-gainers-pmi-advances-artificial-heart-cue-makes-board-changes-cing-despite-crl
- N4 | 2026-06-02 | www.nasdaq.com | FDA Issues CRL To Cingulate Requesting CMC Information On ADHD Drug CTx-1301; Stock Up | https://www.nasdaq.com/articles/fda-issues-crl-cingulate-requesting-cmc-information-adhd-drug-ctx-1301-stock
- N5 | 2026-06-02 | www.nasdaq.com | Cingulate Receives FDA Complete Response Letter For ADHD Drug CTx-1301 | https://www.nasdaq.com/articles/cingulate-receives-fda-complete-response-letter-adhd-drug-ctx-1301
- N6 | 2026-04-28 | www.nasdaq.com | Biotech Stocks Facing FDA Decision In May 2026 | https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-may-2026
- N7 | 2025-12-08 | www.nasdaq.com | Ascendiant Capital Maintains Cingulate (CING) Buy Recommendation | https://www.nasdaq.com/articles/ascendiant-capital-maintains-cingulate-cing-buy-recommendation
- N8 | 2025-11-19 | www.nasdaq.com | Roth Capital Maintains Cingulate (CING) Buy Recommendation | https://www.nasdaq.com/articles/roth-capital-maintains-cingulate-cing-buy-recommendation-0
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


